Narrow-band UVB phototherapy for severe atopic dermatitis

Fungal Allergens

“…They have recently been confirmed by an independent report which suggested that no special cooling system is required in order to achieve the excellent therapeutic effects reported by George et al 20 In our hands, 311 nm UVB therapy has been found Phototherapy for atopic dermatitis X J. Krutmann to be ideal for following UVA-1 therapy: UVA-1 is used in the initial phase of treatment to manage acute, severe exacerbations of atopic dermatitis 5 and is then replaced by 311 nm UVB therapy, which is an effective (and presumably safe) means of maintenance therapy. They have recently been confirmed by an independent report which suggested that no special cooling system is required in order to achieve the excellent therapeutic effects reported by George et al 20 In our hands, 311 nm UVB therapy has been found Phototherapy for atopic dermatitis X J. Krutmann to be ideal for following UVA-1 therapy: UVA-1 is used in the initial phase of treatment to manage acute, severe exacerbations of atopic dermatitis 5 and is then replaced by 311 nm UVB therapy, which is an effective (and presumably safe) means of maintenance therapy.…”

Narrowband UVB phototherapy in skin conditions beyond psoriasis

“…Similar positive results have previously been supported in open prospective and retrospective trials on patients with moderate to severe adult or childhood AD using NB UVB as an adjunctive treatment combined with topical steroids. [13][14][15] In the above-mentioned studies, NB UVB did not only decrease the total clinical score, but also substantially reduced the use of potent steroids. Moreover, Schiffner et al 16 conducted an uncontrolled multicenter trial on combined treatment with NB UVB and salt water baths in outpatients with AD.…”

Phototherapy with Narrowband vs Broadband UVB

“…In a recent study, Pasic et al (42) combined nUVB with UVA for AD in children and showed >90% reduction of the SCORAD index in 45.4% and 70-90% reduction in another 22.7% of patients. Hudson-Peacock et al (87) described a response rate of 81% with complete clearance in 43% for nUVB twice weekly. The first randomized investigator-blinded, half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus nUVB in patients with severe chronic AD found equal effectiveness after a mean duration of 40 days when used three times a week in equi-erythemogenic doses (88).…”